![\"Medical](\"https:\/\/www.jamasoftware.com\/media\/2025\/06\/DOGE-Impacted-FDA-Blog.png\")
<\/h2>\n<\/h2>\nThe Center for Devices and Radiological Health<\/a> (CDRH) is a key branch of the FDA<\/a> that is responsible for ensuring the safety and effectiveness of medical devices. Companies interact with the CDRH through premarket submissions, quality inspections, recalls, and a variety of other activities.<\/p>\n In 2025, the Department of Government Efficiency (DOGE) was established to streamline federal operations, reduce redundancy, and improve cost-effectiveness across agencies. While its goals are rooted in efficiency, the implementation has led to substantial structural and operational shifts that will have a profound impact on the industry.<\/p>\n For companies developing medical devices, understanding these changes is essential for navigating the evolving regulatory landscape. This blog will help you learn all about those changes and provide actionable strategies to stand above the competition while navigating the new frontier.<\/p>\n Workforce Restructuring<\/u><\/a><\/strong><\/p>\n One of the most immediate and highly publicized impacts has been a reduction in staffing. The CDRH has experienced layoffs, hiring freezes, and a mandated attrition ratio. These changes have affected teams working on new technologies, slowing down review processes and resulting in a reduction in internal expertise.<\/p>\n Budget and Operational Adjustments<\/strong><\/p>\n DOGE reforms have also reduced discretionary funding, increasing the CDRH\u2019s reliance on user fees from industry sponsors. This shift has created operational bottlenecks, particularly in areas not directly supported by these fees, such as early-stage innovation and public health initiatives.<\/p>\n Regulatory Process Reforms<\/strong><\/p>\n With fewer staff and resources, the CDRH has had to adjust some of its regulatory workflows. It has been reported that pre-submission meetings are less frequent, and review timelines have lengthened. While the agency remains committed to scientific rigor, the capacity to provide interactive feedback has diminished.<\/p>\n Proposed Guidance Still Moving Forward<\/strong><\/p>\n Despite the challenges mentioned above, CDRH plans to continue advancing its strategic priorities. The FDA has released its 2025 guidance agenda<\/a> which includes the following amongst a larger list of items:<\/p>\n These initiatives reflect CDRH\u2019s ongoing commitment to modernization, even amid structural constraints resulting from DOGE actions.<\/p>\n AI Use in Submissions: A New Frontier<\/u><\/a><\/strong><\/p>\n In another move to improve efficiency and modernize the agency, the FDA has begun using Elsa, a generative AI tool to assist in the scientific review of medical device submissions. This tool will help automate repetitive tasks such as document parsing and data extraction, allowing human reviewers to focus on more complex portions during the evaluation. The rollout is expected to be complete by mid-2025, with early results showing promise in reducing review times and improving consistency.<\/p>\n For those in the medical device industry, these changes present both challenges and opportunities. Companies that embrace the changes and take a proactive approach to interacting with the FDA will find themselves at the forefront of the new era.<\/p>\n Here are some key approaches to consider:<\/p>\n When navigating regulatory pressures, Jama Software is the trusted partner MedTech companies need<\/a>. Our platform empowers organizations to overcome compliance challenges while maximizing efficiency. Here’s how Jama Connect will help you navigate the changes at the FDA:<\/p>\n To streamline product development, tackle complex compliance requirements, and stay ahead in the fast-evolving MedTech landscape, consider partnering with Jama Software. Curious how Jama Software can help your team thrive? Learn More Today.<\/a><\/p>\nKey Changes to CDRH Under DOGE<\/h3>\n
\nRELATED: <\/strong>Jama Connect\u00ae<\/sup> for Medical Device & Life Sciences Development Datasheet<\/a><\/span><\/span><\/h4>\n
\nStrategic Reforms Planned for the CDRH<\/h3>\n
\n
Proven Strategies for Navigating the Changes<\/h3>\n
\n
\nRELATED: <\/strong>Buyer\u2019s Guide: Selecting a Requirements Management and Traceability Solution for Medical Device & Life Sciences<\/a><\/span><\/span><\/h4>\n
\nHow Jama Software Can Support Your Success<\/h3>\n
\n